9th April 2021
Hybrid Congress

Optimizing Immunotherapy

New Approaches, Biomarkers,
Sequences and Combinations
Registration / Access
Symposium Director
Dr. Joaquim Bellmunt, MD, PhD

Associate Professor, Harvard Medical School. IMIM Senior Researcher. Cancer Research Program
Add the event to your Calendar
Google Outlook iCal
Co-director
Dr. Edurne Arriola, MD, PhD

Head of Lung and GU Unit, Medical Oncology Department, Hospital del Mar. IMIM Researcher. Cancer Research Program

Program

08.30 – 08.55
Registration
08.55 – 09.05
Welcome and Opening
Joaquim Bellmunt — Edurne Arriola
09.05 – 09.20
Keynote Lecture
Mechanisms of Resistance to Immunotherapy
Antoni Ribas
09.20 – 10.40
Table 1
Recent Advances of Immunotherapy in the Clinic

Moderator: Alejo Rodríguez-Vida
09.20 – 09.30
Small Cell Lung Cancer (SCLC)
Ernest Nadal
09.30 – 09.40
Breast
Mafalda Oliveira
09.40 – 09.50
Hepatocellular Carcinoma (HCC)
Josep Llovet
09.50 – 10.00
Discussion
10.00 – 10.20
New advances in urothelial cancer: Adjuvant and switch maintenance
Begoña P. Valderrama
10.20 – 10.30
New Surrogates for IO in the Neoadjuvant Setting of NSCLC (Major Pathological Response)
Mariano Provencio
10.30 – 10.40
Discussion
10.40 – 10.50
Coffee
10.50 – 12.55
Table 2
Biomarkers in Immunotherapy

Moderator: Joan Albanell
10.50 – 11.05
Computational Biology: New Trends to Personalize Immunotherapy of Cancer
Mar Alba
11.05 – 11.20
Integrating AI in the Predicting Algorithms of IO
David Casadevall
11.20 – 11.35
Immune Phenotype (Subpopulations) as Predictors of IO Response
Pedro Simões da Rocha
11.35 – 11.45
Discussion
11.45 – 12.00
Microbiome as Predictor of Benefit and Therapeutic Strategy
Guillem Argiles
12.00 – 12.10
New Clinical Trial Endpoints in IO
Meredith Regan
12.15 – 12.25
The Role of ctDNA in Predicting IO Response/Relapse
Tom Powles
12.25 – 12.40
Epigenomics as Predictors for IO Benefit
Manel Esteller
12.40 – 12.55
Discussion
12.55 – 14.00
Lunch
14.00 – 15.35
Table 3
Futures Perspectives on Immunotherapy
Moderator: Joaquín Arribas
14.00 – 14.15
Neoantigen Cancer Vaccines
Leticia de Mattos
14.15 – 14.30
Tumor-Infiltrating Lymphocytes (TIL)
Alena Gros
14.30 – 14.45
CAR T-Cells
Anna Bigas
14.45 – 14.55
Discussion
14.55 – 15.10
Combination: Targeted Therapy +IO
Antonio Calles
15.10 – 15.25
Combination: IO + IO
Pedro Berraondo
15.25 – 15.35
Discussion
15.35
Closing Remarks
Joaquim Bellmunt
Download PDF

Speakers

Mar Alba
ICREA Research Professor. Evolutionay Genomics Group, Research Programme on Biomedical Informatics (GRIB). IMIM-UPF
Joan Albanell
Head of the Medical Oncology Department Hospital del Mar. Head of the CancerResearch Program. IMIM
Guillem Argilés
Visiting Investigator at Memorial Sloan Kettering Cancer Center
Joaquin Arribas
IMIM Director. Research Director of the Mar Health Parc (PSMAR). Barcelona
Edurne Arriola
Head of Lung and GU Unit, Medical Oncology Department, Hospital del Mar. IMIM Researcher. Cancer Research Program
Joaquim Bellmunt
IMIM Senior Researcher. Healthcare Director of the Centro 360 de Excelencia Oncológica GenesisCare Clínica Corachan (GCCC), Barcelona, Spain. Beth Israel Deaconess Medical Center. Associate Professor at Harvard Medical School.
Boston, USA
Pedro Berraondo
Staff Scientist. CIMA Universidad de Navarra. Program of Immunology and Immunotherapy
Anna Bigas
Group Leader, Cancer and Stem Cells IMIM and Scientific Director, CIBERONC
Antonio Calles
Medical Oncologist. Hospital General Universitario Gregorio Marañón
David Casadevall
Data Team Lead. Savana Médica
Leticia de Matos
Group leader of the Neoantigens and Therapeutic Vaccines for Cancer (NeoVaCan) group at IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona
Manel Esteller
Director Josep Carreras Institute
Alena Gros
Principal Investigator of VHIO’s Tumor Immunology and Immunotherapy Group
Josep Llovet
Professor of Medicine. Director, Mount Sinai Liver Cancer Program. Icahn School of Medicine at Mount Sinai.New York. Professor of Medicine-Hepatic Oncology, Professor of Research-ICREA, IDIBAPS- Hospital Clínic. University of Barcelona
Ernest Nadal (ICO)
Medical Oncology Department. Catalan Institute of Oncology (ICO). Duran i Reynals Hospital. Head of the Section of Thoracic, Brain and Head and Neck Tumors in Medical Oncology. Clinical and Translational Research in Solid Tumors (CReST) Group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL).
Principal Investigator. Clinical Sciences Department. University of Barcelona (UB). Campus Bellvitge. Associate Professor
Mafalda Oliveira
Attending Physician . Medical Oncology Department. Breast Cancer Group. Vall d’Hebron University Hospital . Vall d’Hebron Institute of Oncology (VHIO)
Begoña Pérez Valderrama
Medical Oncologist. Hospital Universitario Virgen del Rocío. Sevilla
Thomas Powles
MBBS, MRCP, Clinical Professor of Genitourinary Oncology (HCC) at BartsCancer Institute. Director, Barts Cancer Centre UK
Mariano Provencio
Adjunct Professor of Medicine. The George Washintong University School of Medicine. Chief of Medical Oncology Department Hospital Universitario Puerta de Hierro de Madrid
Meredith Regan
Associate Professor, Division of Biostatistics, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA. Director of the Statistics and Data Management Center of the International Breast Cancer Study Group, Bern, Switzerland
Antoni Ribas
Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center, Director of the Parker Institute for Cancer Immunotherapy Center at UCLA
Alejo Rodríguez-Vida
Consultant Medical Oncologist. Genitourinary Cancer Unit & Early Drug Development Unit. Hospital del Mar. IMIM Researcher Genitourinary cancer Group. Cancer Research Program
Pedro Simões da Rocha
Postdoctoral Fellow. Translational Molecular Pathology department. The University of Texas, MD Anderson Cancer Center
Endorsed by